Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 5/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2751786 | 0.85 | ALDH1A1 (0.64) | ALDH1A1TP53MAPTHPGDPOLB | |
| SCHEMBL2751953 | 0.80 | POLB (0.41) | ALDH1A1TP53HPGDPOLBSMN1; SMN2 | |
| SCHEMBL1722762 | 0.80 | ALDH1A1 (0.46) | ALDH1A1TP53MAPTHPGDPOLB | |
| SCHEMBL2750871 | 0.79 | ALDH1A1 (0.67) | ALDH1A1TP53MAPTHPGDPOLB | |
| SCHEMBL1721511 | 0.79 | SMN1; SMN2 (0.40) | ALDH1A1TP53MAPTLMNAKDM4E | |
| SCHEMBL1722598 | 0.76 | SMN1; SMN2 (0.50) | ALDH1A1TP53MAPTHPGDPOLB | |
| SCHEMBL17082456 | 0.76 | ALDH1A1 (0.43) | ALDH1A1MAPTHPGDPOLBLMNA | |
| SCHEMBL2749474 | 0.76 | ALDH1A1 (0.67) | ALDH1A1TP53MAPTHPGDPOLB | |
| SCHEMBL2750390 | 0.76 | ALDH1A1 (0.67) | ALDH1A1MAPTHPGDLMNAKDM4E | |
| SCHEMBL2750010 | 0.75 | ALDH1A1 (0.58) | ALDH1A1TP53MAPTHPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586755-B2 | Substituted nicotinamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2013-11-19 | — | — | US | disclosed |
| US-8586755-B2 | Substituted nicotinamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2013-11-19 | — | — | US | disclosed |
| US-20120184550-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2012-07-19 | — | — | US | disclosed |
| US-20120184550-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2012-07-19 | — | — | US | disclosed |
| US-20120184550-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2012-07-19 | — | — | US | disclosed |
| US-8178684-B2 | Substituted nicotinamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2012-05-15 | — | — | US | disclosed |
| US-8178684-B2 | Substituted nicotinamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2012-05-15 | — | — | US | disclosed |
| US-8178684-B2 | Substituted nicotinamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2012-05-15 | — | — | US | disclosed |
| WO-2010102809-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2010-09-16 | — | — | WO | disclosed |
| US-20100234429-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234429-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234429-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184550-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | KCNQ2, KCNQ1, KCNQ3 | ALDH1A1 2196/4885TP53 4182/4885MAPT 216/4885 |
| US-20100234429-A1 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS | KCNQ1, KCNQ2, KCNQ3 | ALDH1A1 3206/4885TP53 4510/4885MAPT 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.